Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 18/20 | 0.48 |
| ▸ | THRB | P10828 | 8/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217993 | 0.90 | TGFBR1 (0.50) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL24312339 | 0.80 | TGFBR1 (0.66) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL24312342 | 0.77 | TGFBR1 (0.60) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL23217945 | 0.77 | TGFBR1 (0.47) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL24312341 | 0.75 | THRB (0.57) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL23217956 | 0.72 | TGFBR1 (0.47) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL23218013 | 0.68 | PDK2 (0.41) | TGFBR1 | |
| SCHEMBL414544 | 0.66 | TGFBR1 (1.00) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL23217901 | 0.66 | TGFBR1 (0.54) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL412655 | 0.64 | TGFBR1 (0.82) | TGFBR1THRBMAPK14TGFBR2MAP3K20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021072330-A1 | GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |